NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SAGE

Sage Therapeutics Inc

Jun 30 • 04:00PM ET

9.12

Dollar change -0.03
Percentage change -0.33	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN AMGN VRTX LLY NBIX GILD ACAD MRNA INCY

| Held by: IWM VTI VXF IWN IBB SCHA VTWO PRFZ DFAT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.80	Insider Own	12.03%	Shs Outstand	62.54M	Perf Week	-1.94%
Market Cap	571.11M	Forward P/E	-	EPS next Y	-2.76	Insider Trans	0.00%	Shs Float	55.09M	Perf Month	39.88%
Enterprise Value	159.12M	PEG	-	EPS next Q	-0.94	Inst Own	85.56%	Short Float	9.53%	Perf Quarter	10.14%
Income	-354.40M	P/S	12.05	EPS this Y	46.38%	Inst Trans	-6.58%	Short Ratio	3.36	Perf Half Y	66.42%
Sales	47.40M	P/B	1.39	EPS next Y	22.03%	ROA	-57.29%	Short Interest	5.25M	Perf YTD	67.96%
Book/sh	6.55	P/C	1.35	EPS next 5Y	35.62%	ROE	-63.53%	52W High	13.47 -32.29%	Perf Year	-15.87%
Cash/sh	6.77	P/FCF	-	EPS past 3/5Y	5.47% 13.20%	ROIC	-84.40%	52W Low	4.62 97.40%	Perf 3Y	-74.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	86.99% 43.12%	Gross Margin	81.37%	Volatility	1.44% 3.04%	Perf 5Y	-78.86%
Dividend TTM	-	EV/Sales	3.36	EPS Y/Y TTM	30.94%	Oper. Margin	-758.97%	ATR (14)	0.29	Perf 10Y	-87.07%
Dividend Ex-Date	-	Quick Ratio	9.13	Sales Y/Y TTM	-47.94%	Profit Margin	-747.61%	RSI (14)	72.76	Recom	2.88
Dividend Gr. 3/5Y	- -	Current Ratio	9.13	EPS Q/Q	44.25%	SMA20	14.62%	Beta	0.28	Target Price	8.90
Payout	-	Debt/Eq	0.03	Sales Q/Q	77.97%	SMA50	23.31%	Rel Volume	1.73	Prev Close	9.15
Employees	353	LT Debt/Eq	0.02	Earnings	Apr 29 AMC	SMA200	31.17%	Avg Volume	1.56M	Price	9.12
IPO	Jul 18, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.53% 0.34%	Trades		Volume	2,704,785	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-25	Resumed	BofA Securities	Underperform	$5
Nov-21-24	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$4
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-04-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$10 → $4
Jul-30-24	Downgrade	TD Cowen	Buy → Hold	$16 → $10
Jul-25-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $12
May-29-24	Initiated	Robert W. Baird	Neutral	$15
May-29-24	Initiated	Citigroup	Sell	$8
Apr-17-24	Downgrade	BofA Securities	Neutral → Underperform	$24 → $14
Dec-12-23	Initiated	Deutsche Bank	Hold	$21
Aug-08-23	Downgrade	Needham	Buy → Hold
Aug-08-23	Downgrade	Goldman	Buy → Neutral	$22
Aug-08-23	Downgrade	Canaccord Genuity	Buy → Hold	$64 → $21
Aug-07-23	Downgrade	Wedbush	Outperform → Neutral	$51 → $22
Aug-07-23	Downgrade	Stifel	Buy → Hold	$60 → $22
Aug-07-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$71 → $25
Aug-07-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-07-23	Downgrade	BofA Securities	Buy → Neutral	$66 → $25
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Mar-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$40 → $60

Show Previous Ratings

Jun-23-25 07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-18-25 09:45AM	H.C. Wainwright sees potential competition for Sage from Biogen (TipRanks)
Jun-17-25 02:36PM	SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal (Zacks)
11:10AM	Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? (Zacks)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
04:21PM	Loading…
Jun-16-25 04:21PM	Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics (Investor's Business Daily) +35.37%
07:42AM	Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know. (Barrons.com)
11:43AM	Supernus makes depression drug play with $795m Sage buyout (Pharmaceutical Technology)
09:16AM	Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million (Investor's Business Daily)
08:17AM	Sage, following Setbacks, to sell to Supernus for $561M (BioPharma Dive)
07:00AM	Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio (GlobeNewswire)
May-29-25 11:30AM	Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report? (Zacks)
May-01-25 12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
03:17AM	Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ... (GuruFocus.com)
10:33PM	Loading…
Apr-29-25 10:33PM	Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:15PM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates (Business Wire)
Apr-25-25 09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
Apr-24-25 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-22-25 10:01AM	Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-15-25 06:30AM	Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 (Business Wire)
Apr-09-25 05:11PM	Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story (Seeking Alpha) +8.29%
05:34AM	Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag (Seeking Alpha)
Mar-27-25 05:20PM	Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-13-25 11:30AM	Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-04-25 04:15PM	Sage Therapeutics Announces R&D Leadership Transition (Business Wire)
Mar-01-25 03:19PM	Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
12:30PM	Loading…
Feb-25-25 12:30PM	Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-13-25 10:43AM	Sage Therapeutics price target lowered to $12 from $14 at Scotiabank (TipRanks)
Feb-12-25 10:49AM	Q4 2024 SAGE Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:12AM	Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ... (GuruFocus.com)
Feb-11-25 05:20PM	Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates (Business Wire)
Feb-04-25 10:00AM	Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-28-25 04:30PM	Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 (Business Wire)
07:28AM	Sage rejects Biogens $469m takeover bid (Pharmaceutical Technology)
Jan-27-25 09:28AM	Sage rejects Biogen's $469 million takeover offer, says offer undervalues company (Reuters)
09:20AM	Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogens Unsolicited Acquisition Proposal (Business Wire)
Jan-14-25 09:41AM	Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist (TipRanks)
09:40AM	Biogen bid for Sage does not change narrative, says BMO Capital (TipRanks)
09:03AM	Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? (Zacks)
Jan-13-25 03:12PM	Biogen proposes acquisition of partner Sage Therapeutics (Pharmaceutical Technology) +35.14%
11:57AM	Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More (Investopedia)
09:56AM	Biogen Wants to Buy Its Partner Sage for Almost No Premium (Barrons.com)
09:51AM	Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid (Investopedia)
09:38AM	Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? (Benzinga)
07:24AM	Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen (Barrons.com)
07:07AM	Biogens cold and calculated offer to buy Sage receives a mixed reaction on Wall Street (BioPharma Dive)
Jan-12-25 06:00PM	Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-10-25 06:49PM	Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (Business Wire) -5.13% +35.14%
06:37PM	Biogen proposes to buy remaining stake in Sage in $442 million deal (Reuters)
Jan-08-25 06:30AM	Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 (Business Wire)
Jan-06-25 09:55AM	Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to Trade (Zacks)
Dec-23-24 08:46AM	Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? (Zacks)
Dec-17-24 07:20AM	Sage Therapeutics price target lowered to $6 from $10 at Stifel (TipRanks)
Nov-26-24 07:00AM	Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +9.09%
Nov-22-24 06:40AM	Sage Therapeutics price target lowered to $4 from $7 at BofA (TipRanks) +6.60%
Nov-21-24 11:56AM	Sage ends dalzanemdor development following Phase II trial failure (Clinical Trials Arena)
Nov-20-24 10:36AM	After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder (Benzinga)
06:41AM	Sages string of research failures continues (BioPharma Dive)
06:30AM	Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease (Business Wire)
Oct-31-24 07:39AM	Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler (TipRanks) -5.59%
Oct-30-24 07:38AM	Biogen, Sage admit a defeat in major depression (BioPharma Dive) -24.06%
03:13AM	Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Oct-29-24 05:20PM	Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates (Business Wire)
Oct-28-24 10:10AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire) +6.62%
Oct-23-24 10:00AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire)
05:45AM	Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE (PR Newswire)
Oct-22-24 10:01AM	Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-24 03:02PM	State Street Corp's Strategic Acquisition of Sage Therapeutics Shares (GuruFocus.com)
Oct-17-24 03:56PM	Sage lays off 55% of R&D workforce and refocuses pipeline (Pharmaceutical Technology)
12:32PM	Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline (GuruFocus.com)
10:16AM	Sage Therapeutics CFO, GC, CTO to depart in wide restructuring plan (CFO Dive)
10:11AM	After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce (Benzinga)
09:47AM	Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard. (Barrons.com)
08:08AM	Sage to cut one-third of workforce, streamline drug pipeline (BioPharma Dive)
07:00AM	Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE Commercialization and Focus its Development Portfolio (Business Wire)
Oct-15-24 06:30AM	Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire)
Oct-10-24 08:46AM	Sage Therapeutics price target lowered to $8 from $9 at Wedbush (TipRanks)
Oct-08-24 10:53AM	Sage Therapeutics Reports Disappointing Study Results for Alzheimers Treatment (Barrons.com)
09:19AM	After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study (Benzinga)
08:52AM	Talkiatry Expands Postpartum Depression Care Services to Close Gaps in Maternal Mental Healthcare (PR Newswire)
08:21AM	Sage continues downslide as Alzheimers study fails (BioPharma Dive)
07:36AM	Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimers Treatment (Barrons.com)
07:06AM	Sage Therapeutics stock drops after disappointing Alzheimer's trial results (Investing.com)
06:30AM	Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimers Disease (Business Wire)
Oct-04-24 09:14AM	Sage stock slides as RBC cuts rating to Sell on trial results concerns (Investing.com) -5.01%
Sep-29-24 07:54AM	Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-27-24 07:28AM	SAGE Therapeutics SAGE-324 Collaboration with Biogen Ends (TipRanks)
Sep-26-24 10:37AM	Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate (Benzinga)
07:00AM	Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program (Business Wire)
Sep-25-24 11:34AM	Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers (Insider Monkey)
Sep-24-24 05:45AM	Shareholders of Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE (PR Newswire)
Sep-10-24 05:45AM	Sage Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAGE (PR Newswire)
Sep-05-24 08:30AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire)
Aug-30-24 11:31AM	Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound? (Zacks)

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JONAS JEFFREY M	Officer	Dec 10 '24	Proposed Sale	5.53	7,500	41,441		Dec 13 08:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SAGE

Sage Therapeutics Inc

Upgrade your FINVIZ experience